Welcome to our dedicated page for Pulse Biosciences SEC filings (Ticker: PLSE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Pulse Biosciences, Inc. (Nasdaq: PLSE) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures, along with AI-powered summaries to help interpret complex documents. As a medical device developer focused on bioelectric medicine and nanosecond pulsed field ablation (nsPFA) technology, Pulse Biosciences uses its SEC filings to describe clinical programs, financial performance, governance matters and key milestones for its nPulse platforms.
Investors can review Form 10-K and 10-Q filings for detailed discussions of the company’s business, risk factors, research and development spending and revenue from nPulse capital equipment and Vybrance disposables. Form 8-K current reports highlight material events such as FDA Investigational Device Exemption (IDE) approvals for the NANOCLAMP AF and NANOPULSE-AF atrial fibrillation studies, publication of first-in-human thyroid data, initiation of clinical trials, and quarterly business updates and financial results.
The company’s DEF 14A definitive proxy statement outlines corporate governance, board structure, equity incentive plans and executive compensation policies, providing insight into how management and directors are incentivized as Pulse Biosciences advances its nsPFA technology. Other exhibits and schedules within these filings can include information on stockholder votes, amendments to equity plans and non-GAAP financial measures used by management.
On Stock Titan, each PLSE filing is supplemented with AI-generated explanations that clarify technical language, summarize key sections and point out items such as clinical trial descriptions, regulatory designations and capital structure changes. Users can also monitor Form 4 insider transaction filings when available to see how officers and directors transact in company stock. Together, these tools allow investors, analysts and clinicians to quickly understand the implications of Pulse Biosciences’ SEC filings without reading every line of each document.
Richard van den Broek, a director of Pulse Biosciences, was granted a stock option on 08/15/2025 to purchase 30,000 shares of common stock at an exercise price of $16.16 per share. The option becomes exercisable beginning 08/15/2025 and expires 08/15/2035. The shares subject to the option vest in equal monthly installments over one year, with the first installment on 09/15/2025, contingent on continued service.
Mahkam Zanganeh, a director of Pulse Biosciences (PLSE), reported receipt of two stock option grants on 08/15/2025 totaling 54,134 options. Both options have an exercise price of $16.16 and expire on 08/15/2035. The first option covers 30,000 shares and vests in equal monthly installments over one year beginning 09/15/2025. The second covers 24,134 shares and vests in equal quarterly installments over one year beginning 09/05/2025. Ownership after the transactions is reported as 30,000 and 24,134 shares respectively, held directly.
Pulse Biosciences director and 10% owner Robert W. Duggan received two stock option grants on 08/15/2025 totaling 50,792 options to buy common stock at an exercise price of $16.16 per share. One option for 30,000 shares vests monthly over one year beginning 09/15/2025. The second option for 20,792 shares vests quarterly over one year beginning 09/05/2025. Both options expire 08/15/2035. The Form 4 was filed as a single reporting person filing and signed by an attorney-in-fact on 08/19/2025.
Pulse Biosciences director Manmeet Singh was granted a stock option covering 30,000 shares of common stock with an exercise price of $16.16. The option was issued on 08/15/2025, is exercisable through 08/15/2035 and covers 30,000 underlying shares.
The option will vest in equal monthly installments over a one-year period, contingent on the reporting person’s continued service, with the first vesting installment occurring on September 15, 2025. The reporting person holds the option directly.
Pulse Biosciences, Inc. has called a virtual special stockholder meeting in September 2025 to vote on two equity compensation proposals. The first would amend the 2017 Equity Incentive Plan to add 2,000,000 shares of common stock for future awards and expand the definition of “Consultant” so equity can be granted to workers provided through third‑party employers of record.
The second proposal would ratify previously granted stock options under the plan to acquire up to 1,100,000 shares awarded in August 2024 and January 2025 to one executive, certain directors, and key clinical consultants, at exercise prices of $15.65 and $19.58 per share. As of August 2025, the company reports 67,283,347 shares of common stock outstanding, with major stockholder Robert W. Duggan beneficially owning 48,807,125 shares, or 72.3% of the class. The board unanimously recommends voting “FOR” both proposals.
Pulse Biosciences (PLSE) reported no revenue and continues to operate at a loss while advancing its Nano-pulse Stimulation (NPS) product pipeline. Cash and cash equivalents were $106.3 million at June 30, 2025, with total assets of $120.3 million and stockholders' equity of $104.5 million. The company recorded a net loss of $19.2 million for the three months ended June 30, 2025 and $36.0 million for the six months ended June 30, 2025. Operating cash used totaled $26.3 million for the six-month period and stock-based compensation expense was $10.9 million for the same period. The company has an accumulated deficit of $426.5 million and reports no material cash flows from operations.
The company completed a $60.0 million rights offering in July 2024 (majority purchased by Robert Duggan) and has received $63.5 million in cumulative gross proceeds from exercises of related warrants including $14.1 million during the six months ended June 30, 2025. Regulatory and clinical milestones include FDA 510(k) clearances for the nsPFA Percutaneous Electrode System (initial and a second needle size), placement of CellFX at nine U.S. sites with over 140 patient treatments to date, Breakthrough Device designation and TAP enrollment for the cardiac surgical clamp, and active IDE interactions and planned pivotal U.S. trials for cardiac devices.
Pulse Biosciences, Inc. furnished a Form 8-K to report that it announced financial and operational results for the fiscal quarter ended June 30, 2025. The company stated that a press release containing those results is attached as Exhibit 99.1 and is incorporated by reference. The filing clarifies that the information and the exhibit are being furnished and are not to be deemed "filed" under the Exchange Act for purposes of Section 18, nor incorporated by reference in other filings except by specific reference. No numerical financial metrics or narrative detail from the press release are included in this Form 8-K.
Pulse Biosciences, Inc. (Nasdaq: PLSE) filed a Form 8-K announcing the appointment of Steven T. Weber as Vice President of Accounting & Global Corporate Controller, effective 14 Jul 2025. Weber will also assume the role of principal accounting officer, succeeding the prior incumbent (not specified in the filing). The 25-year finance veteran most recently served as SVP, Corporate Controller & PAO at IGM Biosciences and previously held senior roles at Aeglea Biotherapeutics and PwC.
Compensation & equity incentives: Weber’s cash compensation (base salary and target bonus) aligns with existing VP pay bands; specific dollar amounts were not disclosed. He received a non-statutory option for 55,000 shares at an exercise price of $16.03 (close of 11 Jul 2025). Vesting structure:
- Time-based: 27,500 shares vest 25% on the 1-year anniversary then quarterly over three additional years.
- Performance-based: up to 27,500 shares vest in four equal tranches tied to market-cap milestones of $1.5 B, $2.25 B, $3.0 B, and $4.0 B, each requiring 270 consecutive days and no earlier than year-end 2026-2029.
Weber signed standard inventions, confidentiality, non-competition and indemnification agreements. There are no related-party transactions or family relationships disclosed.
Investor takeaways: This is a governance-focused event that strengthens the finance function with a seasoned CPA. The equity package is modest (~0.2% of shares outstanding) and heavily performance-weighted, aligning Weber’s incentives with long-term shareholder value. No immediate financial impact or guidance changes were provided.